AVDL
Avadel Pharmaceuticals plc
Set alert
21.64 USD 0.00 0.00%
21.64 Day range 21.64
52-week range unavailable
- YTD
- +0.42%
- 1 year
- +140.71%
- Open
- 21.64
- Prev close
- 21.64
- Mkt cap
- 2.12B
- Vol
- 35.02M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 21.64
- High
- 21.64
- Forward P/E
- 27.74
- Beta
- 0.00
- Short ratio
- 1.60
- Inst. own
- 86.80%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 2, 2026
- 50-d avg
- 21.52
- 200-d avg
- 15.84
- 1y target
- 20.71
Key statistics
- Market cap
- 2.12B
- Enterprise value
- 2.06B
- Forward P/E
- 27.74
- PEG ratio
- 0.00
- Price / sales
- 8.55
- Price / book
- 21.43
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -0.11%
- Revenue (TTM)
- 248.52M
- Revenue growth
- 54.90%
- Free cash flow
- 2.73M
- Total cash
- 91.58M
- Total debt
- 37.38M
- Return on equity
- -0.32%
- Shares outstanding
- 98.15M
- Short % of float
- 2.38%
- 50-day average
- 21.52
- 200-day average
- 15.84
Analyst view
Consensus: hold
Hold
Price target (mean) 20.71 -4.3% downside
Now 21.64
- Target (low)
- 18.50
- Target (mean)
- 20.71
- Target (high)
- 23.00
Ratings (0m) 9 0 buy · 9 hold · 0 sell
- Strong buy0
- Buy0
- Hold9
- Sell0
- Strong sell0
Next earnings
Mar 2, 2026
Expected Mar 2, 2026. Consensus EPS estimate 0.14429.
Financials — quick view
AVDL Revenue — quarterly 77.47M
AVDL Net income — quarterly 20.00K
AVDL EPS — quarterly 0.00
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 2, 2026 | Dec 1, 2025 | 0.08 | — | — | — |
| Nov 4, 2025 | Sep 1, 2025 | 0.04 | — | — | — |
| Aug 7, 2025 | Jun 1, 2025 | 0.02 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 20, 2025 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Nov 7, 2025 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Oct 28, 2025 | UBS | down | Buy | Neutral |
| Oct 23, 2025 | Leerink Partners | down | Outperform | Market Perform |
| Oct 23, 2025 | HC Wainwright & Co. | down | Buy | Neutral |
| Oct 22, 2025 | Jefferies | down | Buy | Hold |
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland. As of February 12, 2026, Avadel Pharmaceuticals plc operates as a subsidiary of Alkermes plc.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Ireland
- Website
- avadel.com
News
- Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton
- Avadel Pharmaceuticals (NASDAQ:AVDL) Shares Cross Above 200-Day Moving Average – What’s Next?
- Form 8.3 - Avadel Pharmaceuticals plc
- Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market
- Form 8.3 -Avadel Pharmaceuticals plc
- Avadel Pharmaceuticals Announces Outcome of the Court Sanction Hearing
- Form 8.3 -Avadel Pharmaceuticals plc
- Form 8.3 -Avadel Pharmaceuticals plc
- Form 8.3 -Avadel Pharmaceuticals plc
- Form 8.3 -Avadel Pharmaceuticals plc
Your note
Sign in to keep a note on AVDL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AMIN NASEEM M.D. | Director | Stock Award(Grant) | Jul 28, 2025 | 22,000 |
| DIVIS GREGORY J. JR. | Chief Executive Officer | Stock Award(Grant) | Mar 4, 2025 | 221,100 |
| ENDE ERIC J | Director | Stock Award(Grant) | Jul 28, 2025 | 219,900 |
| GLASS GEOFFREY MICHAEL | Director | Stock Award(Grant) | Jul 28, 2025 | 166,979 |
| MCCAMISH MARK ANTHONY | Director | Stock Gift | Feb 3, 2026 | 0 |
| MCHUGH THOMAS S | Chief Financial Officer | Stock Award(Grant) | Mar 4, 2025 | 100,400 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Janus Henderson Group PLC | 7.57% | 7,429,718 | 160.78M | Sep 29, 2025 |
| Blackrock Inc. | 7.17% | 7,041,102 | 152.37M | Dec 30, 2025 |
| Vanguard Group Inc | 5.98% | 5,864,781 | 126.91M | Dec 30, 2025 |
| Gendell, Jeffrey L. | 5.41% | 5,314,810 | 115.01M | Sep 29, 2025 |
| Polar Capital Holdings PLC | 4.07% | 3,999,338 | 86.55M | Sep 29, 2025 |
| Vivo Capital, LLC | 2.73% | 2,684,109 | 58.08M | Sep 29, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.93% | 2,874,464 | 62.20M | Sep 29, 2025 |
| iShares Trust-iShares Russell 2000 ETF | 2.30% | 2,255,170 | 48.80M | Dec 30, 2025 |
| JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | 1.53% | 1,503,297 | 32.53M | Sep 29, 2025 |
| JANUS INVESTMENT FUND-Janus Henderson Venture Fund | 1.47% | 1,441,349 | 31.19M | Sep 29, 2025 |
| Datum One Series Trust-BRANDES INTERNATIONAL SMALL CAP EQUITY FUND | 1.17% | 1,149,273 | 24.87M | Sep 29, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.05% | 1,028,939 | 22.27M | Sep 29, 2025 |